KMPH crashes by over half following Advisory Committee meeting + 60 updates from reporting companies

May 06, 2016 No Comments by

Updates to the Company Pipeline Database for May 5, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary AERI 14.52 Roclatan – Mercury trials Glaucoma Phase 3 Phase 3 Mercury 1 data due 3Q 2016. Mercury 2 trial data due 2Q 2017 AGIO 43.15 AG-348 Pyruvate kinase deficiency Phase 2 […]

Daily News Read more

DVAX PDUFA delayed till December 15. OPK PDUFA set for October 22 + THERF CLDX CYTX OASM OCUL VRTX updates

Apr 28, 2016 No Comments by

Updates to the Company Pipeline Database for April 27, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary CLDX 4.08 Glembatumumab vedotin Cancer – Squamous cell lung cancer Phase 1/2 Phase 1/2 commenced April 2016 CYTX 0.35 ECCS-50 Scleroderma Phase 3 Pivotal trial initiated August 2015. Noted late April 2016 […]

Daily News Read more

CLDX Phase 3 trial discontinued. VCEL PDUFA January 3 + updates for CRBP ADXS NVIV OTIC OTIC SCYX SCYX SPPI XNCR

Mar 07, 2016 No Comments by

Updates to the Company Pipeline Database for March 7, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ADXS 9.27 Axalimogene filolisbac Recurrent cervical cancer Phase 2 Dosing of first patient in expansion cohort of Phase 2 trial commenced March 2016 CLDX 3.79 CDX-110 rindopepimut – ACT IV Cancer- glioblastoma […]

Daily News Read more

PPHM discontinues Phase 3 SUNRISE trial. CARA CR845 placed on clinical hold. AAAP PDUFA date extension + updates for ACHN ALKS AMRN BMRN BNTC CLDX CLVS ESPR GERN HTBX INSM ITCI KERX LJPC MACK MCRB RARE RPTP SGYP TSRO XLRN

Feb 26, 2016 No Comments

Updates to the Company Pipeline Database for February 25, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary AAAP 33.00 Somakit-TATE Diagnose somatostatinreceptor-positive NET lesions PDUFA priority review PDUFA priority review. Extended to June 1 2016 ACHN 6.85 Odalasvir (ACH-3102), simeprevir and ALS-335 Hepatitis C viral infection (HCV) Phase 2a […]

Read more

PTCT receives Refusal to File Letter. CLDX Phase 3 data due March + updates for ALDR AMAG ARIA BCRX ICPT INFI NVIV PRTK PTCT

Feb 24, 2016 No Comments

Updates to the Company Pipeline Database for February 23, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ALDR 19.29 ALD403 Chronic Migraine Phase 2b Phase 2b data due 1Q 2016 ALDR 19.29 ALD403 – PROMISE 1 Frequent episodic migraine Phase 3 Phase 3 topline data due 1H 2017 AMAG […]

Read more

Pipeline updates for ALKS ARDX ATRS BMRN CEMP CLDX CLVS DPRX DYAX EXEL FLXN INFI NKTR TBPH XOMA

Feb 26, 2015 No Comments

Latest updates to the Company Pipeline Database for February 24-25, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated ALKS 71.11 ALKS 5461 Major depressive disorder Phase 2 Phase 3 (two trials) initiated Jun 2014. Data due 2016. Third Phase 3 trial initiated mid 2014. Data due […]

Read more

INCY FDA Approval + Updates for ADMA APRI CLDX EARS NERV

Dec 05, 2014 No Comments

Latest updates to the Company Pipeline Database from December 3 and 4 2014. Refer to the FDA Calendar for upcoming catalysts Ticker Price Drug Indication Stage Link Text Updated ADMA 10.80 RI-002 Primary Immune Deficiency Diseases Phase 3 Phase 3 prelim data released December 2014 met endpoint. Final data due 1Q 2015. BLA filing planned for […]

Read more

EXEL Phase 3 data due 2Q 2015 + upcoming catalyst dates for XNPT IRWD ACHN AQXP + LXRX XOMA updates

Nov 04, 2014 No Comments

Exelixis, Inc. (NASDAQ:EXEL) provided an update noting that top-line results from their pivotal Phase 3 trial METEOR in metastatic renal cell carcinoma, are now anticipated in 2Q 2015. XenoPort, Inc. (Nasdaq: XNPT) provided an update noting that top-line data from their Phase 2 XP23829 trial as a potential treatment for patients with moderate-to-severe chronic plaque-type psoriasis and/or relapsing forms of […]

Read more

Pipeline updates for OPK CLDX ANAC CNAT ACRX GEVA. Offering news for ACAD BLRX

Mar 04, 2014 No Comments

Anacor Pharmaceuticals (NASDAQ:ANAC) announced that following an End-of-Phase 2 meeting with the FDA, a Phase 3 trial of AN2728 for the topical treatment of mild-to-moderate atopic dermatitis is scheduled to commence by the start of May 2014. Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) announced the initiation of a Phase 2 clinical trial of emricasan, in patients with nonalcoholic […]

Read more

CLDX prices offering. ABIO to initiate GENETIC-AF next quarter. CERS completes PMA filing + IDRA news

Dec 04, 2013 No Comments

Celldex Therapeutics, Inc. (Nasdaq:CLDX $26.16) announced the pricing of an underwritten public offering of 7,000,000 shares of its common stock, offered at a price to the public of $24.50 per share for an aggregate offering of $171,500,000 of common stock. Idera Pharmaceuticals, Inc. (Nasdaq: IDRA $2.45) announced that enrollment is open for a Phase 1/2 clinical trial of IMO-8400 in patients with […]

Read more

Updates for VNDA RIGL TRGT CYTR BLRX AVNR PBYI OXGN KYTH CLDX

Aug 07, 2013 No Comments

Vanda Pharmaceuticals Inc.(Vanda) (NASDAQ: VNDA$11.14) announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL $4.14) provided an update that it expects announce a decision about its future plans for fostamatanib in 3Q 2013, as well as Phase 2 data of R343 in allergic asthma. Phase […]

Read more